Non-aqueous Docetaxel Nanodispersion Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The formulation of docetaxel, a highly lipophilic and poorly soluble compound, into therapeutically useful carriers is challenging due to its insolubility in both aqueous and lipid carriers, making it difficult to develop effective pharmaceutical formulations.
Innovation Solution
Non-aqueous, ethanol-free docetaxel liquid nanodispersion formulations are developed, comprising docetaxel, an oil, a non-ionic surfactant, and a non-aqueous solvent with an organic acid component that is soluble in the solvent, where the weight ratio of the non-ionic surfactant is equal to or greater than the non-aqueous solvent, enhancing stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If docetaxel is formulated in traditional aqueous or lipid carriers, then therapeutic administration is enabled, but solubility problems occur due to its highly lipophilic nature
Solution Approach 1:
The patent introduces a non-aqueous solvent as an intermediary medium that bridges the gap between docetaxel's lipophilic nature and the requirement for aqueous administration. This non-aqueous solvent acts as a mediator that can dissolve docetaxel while still allowing for therapeutic application, resolving the contradiction between solubility and formulation capability.
Solution Approach 2:
The patent changes the fundamental parameter of the solvent system from aqueous or traditional lipid-based to a specific non-aqueous solvent system. This parameter change enables docetaxel to be dissolved and formulated in a way that maintains both its lipophilic characteristics and therapeutic usability, addressing the solubility issue while enabling formulation.
2Quantity of substance
If non-aqueous solvents are used to improve docetaxel solubility, then solubility is enhanced, but the formulations become complex and require specific components
Solution Approach 1:
The patent creates a composite formulation system combining multiple components: non-aqueous solvent, surfactant, and docetaxel. This composite approach allows each component to contribute specific functions - the solvent provides dissolution capability, the surfactant enhances stability and solubility, and docetaxel is the active agent. Together they resolve the solubility issue while managing formulation complexity through functional distribution.
Solution Approach 2:
The patent applies local quality by assigning specific functional characteristics to different components of the formulation. The non-aqueous solvent provides bulk dissolution capability, while the surfactant component specifically addresses interfacial stability and solubility enhancement. This functional differentiation allows the formulation to achieve high solubility without requiring all components to be complex, thereby managing overall formulation complexity.
3Ease of manufacture
If traditional formulation methods are used, then manufacturing is simpler, but the formulations are not stable or clear enough for therapeutic use
Solution Approach 1:
The surfactant component acts as an intermediary that stabilizes the interface between the non-aqueous solvent and docetaxel, preventing aggregation and ensuring formulation stability. This intermediary component allows the formulation to maintain stability without requiring complex manufacturing processes, as the surfactant mediates the interaction between other components to achieve stable, clear formulations.
Solution Approach 2:
The patent changes key formulation parameters including the type of solvent (non-aqueous), the ratio of components, and the presence of surfactants to achieve optimal stability. These parameter changes enable the formulation to be stable and clear while maintaining relatively simple manufacturing processes, as the stability is achieved through compositional parameters rather than complex processing requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations produce a clear, stable docetaxel diluted solution with nanosized particles, improving solubility and stability, suitable for therapeutic use without the need for aqueous or ethanol-based solvents, thus overcoming the solubility challenges of docetaxel.
Implementation Method 1
a non-ionic surfactant... wherein the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent
Implementation Method 2
an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent
Data Source
AI summary
Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Alos provided are non-aqueous, ethanol-free docetaxel nanodispersion formulations. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.